ArticleBrain, behavior, & immunity - health2025
Dual inflammation in schizophrenia infected with COVID-19: Impact on cognitive function.
Article in Brain, behavior, & immunity - health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accumulating evidence has shown that cognitive function among schizophrenia is pervasively impaired and has a connection between immune-inflammatory markers. COVID-19 elicited a series of inflammatory cascades. However, in the context of dual inflammation, fluctuations in cognitive function of schizophrenia in the long-term remain unknown. We aimed to explore the effect of dual inflammation on cognitive domains of schizophrenia patients. Methods: This study included 119 schizophrenia patients with COVID-19 (49 recruited in the acute period and 70 recruited 2 years after recovery) and 114 schizophrenia patients without COVID-19, and 13 immune-inflammatory markers in the acute period were measured. Cognitive function of 119 patients with COVID-19 and 98 patients without COVID-19 were measured with Chinese Brief Cognitive Test (C-BCT) during the recruitment. General linear model was used to compare the immune-inflammatory markers, and correlation analysis was used to explore the relationship of inflammatory levels and cognitive function. Results: The peripheral immune-inflammatory levels of schizophrenia with COVID-19 were obviously increased ( Conclusion: This study found that schizophrenia patients with COVID-19 suggested dual inflammation, and cognitive function were impaired under dual inflammation. The cognitive impairment could be reversible in the long-term of recovery of inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.